# Pizarra — PT-pseudo_4bfd4ec864d8 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4bfd4ec864d8
Task: 1

Encounter: Urology - outpatient on 02 Mar 2025.
Referrer: Dr. H. Martens (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 72-year-old male
  - PSA: 11.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.35 ng/mL²
  - PSA velocity: 1.56 ng/mL/yr
  - Prior PSA: 8.3 ng/mL
  - Prostate volume: 31.6 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.833 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NSAIDs
  - Additional notes: PSA 11 ng/mL. PI-RADS 5. PSAD 0.35. Prostate volume 32 mL. DRE nodus. csPCa 0.83.

Vitals: weight 82 kg, height 183 cm, BMI 24.5, BP 118/75 mmHg, HR 66 bpm. Smoking: Non-smoker.

Chief complaint: Current evaluation addresses sustained PSA elevation alongside a newly identified PI-RADS 5 lesion on recent imaging.

History: The patient, a 72-year-old retired plumber, entered urological monitoring after an initial PSA rise in early 2022. He identifies as a non-smoker and currently resides in a ground-floor apartment with his partner, having been widowed. Respiratory management involves tiotropium alongside PRN salbutamol for his COPD. Urinary symptom burden remains low (IPSS 6), characterized mainly by sporadic nocturia, with explicit denial of haematuria or pelvic discomfort. Recreational gardening continues, and he recently finished six physiotherapy visits addressing chronic lower back ache unrelated to prostate pathology. Daily activity features regular neighbourhood walks. Notably, he reports no unexplained weight reduction, skeletal pain, or systemic complaints.

Physical examination: DRE — texture: asymmetrically enlarged gland; mobility: fixed; asymmetry: firm, discrete nodule localized to the right peripheral zone. Abdominal and cardiovascular assessments remain entirely unremarkable. Blood pressure is stable, and cardiac rhythm registers at 66 bpm.

Patient info: retired plumber; Widowed; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Gardening, no structured exercise; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Radiology — chest X-ray (routine); Audiology — hearing test; Physiotherapy — lower back, six sessions.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.60 +/- 0.20   (95% CI 0.20-0.93)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 5.9 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=1.0, psa=11.0, age=72.0, psad=0.35, dre_ord=1.0, vol=31.6, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the specific PSA velocity (1.56 ng/mL/yr) or the full PSA history trend, which is crucial given the high current PSA (11.0 ng/mL) and the prior PSA (8.3 ng/mL). It also missed the context provided by the mpMRI report prose and the full laboratory panel, which might contextualize the PI-RADS 5 finding or PSA density.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests BIOPSY with a wide interval (0.60 +/- 0.20), indicating high uncertainty. A failure mode is the contradiction between the high csPCa predicted probability (0.833) and the prior negative biopsy status. Another failure mode is the DRE finding of a "Nodus" (which is ambiguous) being weighed against the PI-RADS 5, without knowing the specific characteristics of the lesion from the MRI report.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details the extent or characteristics of the PI-RADS 5 lesion, it would refine the risk assessment.
  <document> PSA history (trend / velocity beyond the headline value) -> If the trend shows a rapid, concerning rise, it would increase the urgency for intervention.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial PSA rise in 2022 or any prior discussions about surveillance.
  <document> laboratory results (full panel) -> This could provide context on PSA density or other markers that modify the interpretation of the PI-RADS 5 score.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number.
  
  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_4bfd4ec864d8", "radiology_report": "Subject: Prostate Multiparametric MRI\nReporting Centre: OLVG Amsterdam\nDate: 28 February 2025\nClinical context: PSA 11.0 ng/mL with a PI-RADS 5 designation.\n\nFINDINGS:\nProstate parenchyma occupies a total volume of 31.6 mL. T2-weighted sequences highlight a sharply demarcated, markedly hypointense focus measuring 12 x 9 x 11 mm within the right peripheral zone at the mid-gland level. This area exhibits restricted diffusion on DWI with corresponding low signal intensity on the ADC map. Dynamic contrast-enhanced sequences show early, focal enhancement compared to adjacent tissue. Extracapsular extension, seminal vesicle invasion, suspicious lymphadenopathy, and osseous abnormalities are absent.\n\nIMPRESSION:\nPI-RADS 5 lesion in the right mid-peripheral zone.\nProstate volume 31.6 mL; PSA density 0.35 ng/mL/mL.\ncsPCa predicted probability 0.833."}
  
  **psa_trend**
  {"case_id": "PT-pseudo_4bfd4ec864d8", "psa_trend": [{"date": "Mar 2022", "val": 4.2}, {"date": "Dec 2022", "val": 5.3}, {"date": "Sep 2023", "val": 6.8}, {"date": "Jun 2024", "val": 8.6}, {"date": "Mar 2025", "val": 11.0}]}
  
  **previous_notes**
  {"case_id": "PT-pseudo_4bfd4ec864d8", "previous_notes": [{"date": "13 Mar 2023", "author": "Dr. H. Martens (GP)", "text": "Clinical review on 13 March 2023 addressed a PSA increase to 6.3 ng/mL. Subsequent multiparametric MRI and systematic core biopsy yielded negative results for malignancy, with the encounter logged for ongoing urological monitoring."}]}
  
  **lab_results**
  {"case_id": "PT-pseudo_4bfd4ec864d8", "laboratory_results": [{"name": "PSA", "val": "11.0 ng/mL", "date": "10 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.62 ng/mL", "date": "10 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "15%", "date": "10 Feb 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "13.8 g/dL", "date": "10 Feb 2025", "flag": ""}, {"name": "WBC", "val": "4.0 x10^9/L", "date": "10 Feb 2025", "flag": ""}, {"name": "Platelets", "val": "211 x10^9/L", "date": "10 Feb 2025", "flag": ""}, {"name": "Creatinine", "val": "95 umol/L", "date": "10 Feb 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "10 Feb 2025", "flag": ""}, {"name": "Testosterone", "val": "15.2 nmol/L", "date": "10 Feb 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "75 U/L", "date": "10 Feb 2025", "flag": ""}, {"name": "LDH", "val": "204 U/L", "date": "10 Feb 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PI-RADS 5 lesion in the right mid-peripheral zone
  - PSA velocity of 1.56 ng/mL/yr (from initial prompt data, confirmed by trend)
  - csPCa predicted probability of 0.833
  
  AGAINST sampling this patient now:
  - Prior biopsy was Negative
  - Previous notes indicate prior negative biopsy and ongoing monitoring.
  - Free PSA is 15% (which is often a factor in risk stratification, though not explicitly stated as a contraindication here).

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk imaging finding (PI-RADS 5) and the concerning PSA velocity, which contradicts the prior negative biopsy result. This leans towards the statistical prior's suggestion of BIOPSY, as the retrieved data provides strong clinical justification for re-evaluation.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

No frozen image embeddings are on file for this patient, so the image-embedding head could not be run. This contributes NO evidence in either direction — do not read the absence of a score as reassurance.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports re-sampling due to a high-risk PI-RADS 5 lesion and a concerning PSA velocity of 1.56 ng/mL/yr. This finding directly contradicts the prior negative biopsy result, which is a key factor driving the decision. The high csPCa predicted probability of 0.833 further justifies intervention, overriding the deferral guideline for a PI-RADS 5 finding.

Variables that carried weight: bx=decisive, age=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
